Novalgen_logo_on_white.jpg
NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors
January 09, 2023 07:00 ET | NovalGen Ltd.
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today...
immunocore-logo-2018
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq:...
immunocore-logo-2018
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
December 08, 2022 06:30 ET | Immunocore Holdings Limited
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4...
immunocore-logo-2018
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
December 02, 2022 07:30 ET | Immunocore Holdings Limited
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions ...
immunocore-logo-2018
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...
Novalgen_logo_on_white.jpg
NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting
November 03, 2022 09:58 ET | NovalGen Ltd.
-Updated clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL -- Pre-clinical data for a first in class half-life extended T Cell engager...
immunocore-logo-2018
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany,...
immunocore-logo-2018
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
immunocore-logo-2018
Immunocore Announces $140 Million Private Placement Financing
July 18, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces $140 Million Private Placement Financing (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq:...
immunocore-logo-2018
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
July 11, 2022 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase...